NEW HAVEN, Conn. and MONMOUTH JUNCTION, N.J., July 11, 2022 /PRNewswire/ — DiamiR, a developer of innovative blood-based diagnostic tests for brain health and other diseases, today announced the appointment of Alidad Mireskandari, Ph.D., MBA as Chief Executive Officer (CEO), effective immediately. Dr. Mireskandari has over 12 years of life sciences industry experience with a focus on molecular diagnostic test development and commercialization, including regulatory and reimbursement expertise. Dr. Mireskandari most recently served as Chief Development Officer of Interpace Biosciences, and prior to that as President & CEO of JS Genetics. From 2000 to 2009, Dr. Mireskandari was a hedge fund manager in charge of Life Sciences trading portfolios of Nomura Securities, BNP Paribas and Raeburn Advisors. Prior to this experience, he was a research fellow at National Institutes of Health’s National Cancer Institute.